In the last trading session, 1.81 million shares of the BioXcel Therapeutics Inc (NASDAQ:BTAI) were traded, and its beta was -0.02. Most recently the company’s share price was $0.39, and it changed around $0.02 or 5.86% from the last close, which brings the market valuation of the company to $20.69M. BTAI currently trades at a discount to its 52-week high of $4.17, offering almost -969.23% off that amount. The share price’s 52-week low was $0.30, which indicates that the current value has risen by an impressive 23.08% since then. We note from BioXcel Therapeutics Inc’s average daily trading volume that its 10-day average is 1.04 million shares, with the 3-month average coming to 626.70K.
BioXcel Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.50. If we narrow it down even further, the data shows that 0 out of 5 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 2 recommended BTAI as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. BioXcel Therapeutics Inc is expected to report earnings per share of -0.31 for the current quarter.
BioXcel Therapeutics Inc (NASDAQ:BTAI) trade information
Instantly BTAI has showed a green trend with a performance of 5.86% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 0.4400 on recent trading dayincreased the stock’s daily price by 11.36%. The company’s shares are currently down -86.65% year-to-date, but still up 24.86% over the last five days. On the other hand, BioXcel Therapeutics Inc (NASDAQ:BTAI) is -15.09% down in the 30-day period. We can see from the shorts that 0.35 million shares have been sold at a short interest cover period of 0.93 day(s).
The consensus price target as assigned by Wall Street analysts is $1, which translates to bulls needing to increase their stock price by 61.0% from its current value. Analyst projections state that BTAI is forecast to be at a low of $1 and a high of $1.
BioXcel Therapeutics Inc (BTAI) estimates and forecasts
BioXcel Therapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -69.23 percent over the past six months and at a 70.73% annual growth rate that is well above the industry average of 16.70%. The year-over-year growth rate is expected to be 175.66%, up from the previous year.
Consensus estimates provided by 5 financial analysts predict the company will bring in an average of 1.24M in revenue for the current quarter. Analysts predict that the company’s current quarter sales will jump, forecast at 230.35%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -35.97%.
BTAI Dividends
BioXcel Therapeutics Inc’s next quarterly earnings report is expected to be released in January.
BioXcel Therapeutics Inc (NASDAQ:BTAI)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 20.06% of BioXcel Therapeutics Inc shares, and 8.76% of them are in the hands of institutional investors. The stock currently has a share float of 10.96%. BioXcel Therapeutics Inc stock is held by 72.0 institutions, with ARMISTICE CAPITAL, LLC being the largest institutional investor. By 2024-06-30, it held 9.6767% of the shares, which is about 2.99 million shares worth $3.82 million.
FMR LLC, with 7.1439% or 2.21 million shares worth $2.82 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
